Feb 7, 2025 03:47PM
Feb 7, 2025 03:46PM
Feb 6, 2025 08:40AM
Feb 6, 2025 08:39AM
Feb 5, 2025 08:00AM
Feb 3, 2025 11:40AM
Feb 1, 2025 07:40AM RVNC DEADLINE FOR LEADERSHIP is March 4, 2025 in a Securities Fraud Lawsuit - Contact Kaplan Fox
Jan 31, 2025 10:40AM
Jan 31, 2025 07:30AM
Jan 30, 2025 10:47AM
Jan 30, 2025 10:47AM
Jan 30, 2025 09:39AM
Jan 29, 2025 01:40PM
Jan 27, 2025 04:00PM RVNC INVESTORS: Kirby McInerney LLP Reminds Revance Therapeutics, Inc. Investors of Important Deadline and Encourages Investors to Contact the Firm
Jan 21, 2025 08:03AM
Jan 21, 2025 08:00AM
Jan 21, 2025 08:00AM
Jan 13, 2025 01:10PM
Jan 13, 2025 08:30AM
Jan 11, 2025 07:10AM
Jan 10, 2025 11:09AM RVNC Deadline to Lead in Securities Fraud Lawsuit is March 4, 2025 - Contact Kaplan Fox & Kilsheimer LLP
Jan 9, 2025 10:09AM
Jan 8, 2025 07:09PM
Jan 6, 2025 08:00PM
Jan 6, 2025 09:01AM
Jan 6, 2025 09:00AM
Dec 12, 2024 08:00AM
Dec 9, 2024 10:40AM Revance Therapeutic (RVNC) PT Lowered to $3.10 at Stifel
Dec 9, 2024 08:30AM
Nov 7, 2024 04:05PM
Aug 12, 2024 11:12AM
Aug 12, 2024 10:07AM
Aug 12, 2024 08:00AM
Aug 12, 2024 08:00AM
Aug 8, 2024 04:05PM Revance Reports Second Quarter 2024 Financial Results, Provides Corporate Update
Jun 14, 2024 04:05PM
May 9, 2024 04:07PM
May 9, 2024 04:06PM
May 9, 2024 04:05PM
Apr 12, 2024 08:00AM
Feb 28, 2024 04:05PM
Feb 2, 2024 08:00AM Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®
Jan 8, 2024 08:15AM
Jan 8, 2024 08:00AM
Nov 8, 2023 04:06PM
Nov 8, 2023 04:06PM
Nov 8, 2023 04:05PM
Oct 26, 2023 08:00AM
Sep 19, 2023 09:08AM Revance Therapeutics (RVNC) Provides Corporate Update
Sep 19, 2023 09:00AM

1,154,893 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All